Certara, Inc. reported a notable increase in financial performance for the third quarter of 2025, with revenues reaching $104.6 million, a 10% increase from $94.8 million in the same period last year. For the nine months ending September 30, 2025, total revenues were $315.2 million, up 11% from $284.8 million in 2024. The growth was primarily driven by a business acquisition that contributed approximately $17 million to revenue, alongside strong demand for the company's technology-enabled services and software products.
The company's net income for the third quarter was $1.5 million, a significant turnaround from a net loss of $1.4 million in the prior year. For the nine-month period, net income was $4.3 million, compared to a net loss of $18.6 million in 2024. This improvement was attributed to increased revenues, a decrease in operating expenses, and a reduction in interest expenses. Operating expenses rose to $61.9 million for the quarter, up from $55 million a year earlier, largely due to higher costs in sales and marketing, research and development, and general administrative expenses.
Certara's operational metrics showed a positive trend, with software revenues increasing by 22% to $43.8 million, while service revenues grew by 3% to $60.8 million. The company reported a total of 94,000 users of its software products, with a customer base that includes over 2,400 life sciences companies and academic institutions. The company also noted a strong net retention rate of 103.9% for the third quarter, indicating effective customer retention and expansion strategies.
In terms of strategic developments, Certara completed the acquisition of Chemaxon, a cheminformatics company, in October 2024, which has been integrated into its operations. The company has also been investing in expanding its software capabilities, particularly in artificial intelligence and machine learning, to enhance its product offerings. As of September 30, 2025, Certara had a cash balance of $172.7 million and a long-term debt of $296.3 million, reflecting a stable financial position.
Looking ahead, Certara anticipates continued growth driven by the increasing adoption of biosimulation technologies in drug development and regulatory processes. The company plans to invest further in research and development, sales and marketing, and potential acquisitions to enhance its market position. The management remains optimistic about the future, citing a favorable regulatory environment and ongoing demand for its innovative solutions in the biopharmaceutical industry.
About Certara, Inc.
Certara, Inc. is a global leader in biosimulation technology and solutions for the biopharmaceutical industry. It provides software and services that utilize modeling, simulation, and AI to optimize drug discovery, development, and regulatory processes. Its platforms support decision-making, improve success rates, and reduce costs across the entire drug lifecycle, serving pharmaceutical companies, regulators, and academic institutions worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.